Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, FL on June 10-13, 2024.
賓夕法尼亞州拉德諾爾，2024年6月3日（環球資訊） - 臨床階段生物製藥公司Mineralys Therapeutics，Inc.（NASDAQ：MLYS），專注於開發治療高血壓，慢性腎臟病（CKD）和其他由失調醛固酮驅動的疾病的藥物，今天宣佈管理層將參加高盛45週年全球醫療保健會議的爐邊談話，該會議將於2024年6月10日至13日在佛羅里達州邁阿密舉行。th高盛45週年全球醫療保健會議：
| Goldman Sachs 45th Annual Global Healthcare Conference: | |
| Date: | Tuesday, June 11, 2024 |
| Time: | 4:00pm EDT |
| Format: | Fireside Chat |
| Webcast Link | |
| 高盛th年度全球醫療保健大會: | |
| 日期： | 2024年6月11日星期二 |
| 時間： | 美國東部夏令時下午4:00 |
| 格式： | 爐邊談話 |
| 網絡直播鏈接 | |
A live webcast of the fireside chat can be accessed under "News and Events" on the Investor Relations section of the Mineralys website at . A replay of the fireside chat will be available on the Company's website for approximately 90 days.
可以在Mineralys網站的“新聞與事件”下訪問爐邊談話的實時網絡直播。公司網站上的爐邊談話重播將在大約90天內提供。
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit Follow Mineralys on LinkedIn and Twitter.
關於Mineralys Therapeutics
Mineralys Therapeutics是一家臨床階段的生物製藥公司，專注於開發針對高血壓，CKD和其他由失調醛固酮驅動的疾病的藥物。其首個產品候選藥lorundrostat是一種專有的口服高選擇性醛固酮合成酶抑制劑，Mineralys Therapeutics正在開發用於受失調醛固酮影響的心臟腎臟疾病，包括高血壓和CKD。Mineralys位於賓夕法尼亞州拉德諾爾，由Catalys Pacific創立。有關更多信息，請訪問Follow Mineralys在LinkedIn和Twitter上。
Contact:
聯繫方式：
Investor Relations
investorrelations@mineralystx.com
投資者關係
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
媒體關係
Tom Weible
Elixir Health公共關係
電話：（1）515-707-9678
電子郵件：tweible@elixirhealthpr.com
譯文內容由第三人軟體翻譯。